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Abstract
Sexually transmitted diseases (STDs) can be transmitted through genital-genital, oro-
genital, or anogenital contacts and remain to be a public health concern worldwide. 
Approximately one million people around the world are believed to be newly infected 
with sexually transmitted infections (STIs) each day. Numerous causative agents includ-
ing bacteria, viruses, protozoa, yeast, and fungi are responsible for STIs; however, viruses 
exhibit more serious risks, probabilities and outcomes of STDs than other organisms. 
The most lethal viral STIs are human immunodeficiency virus-1 (HIV), herpes sim-
plex viruses 1 and 2 (HSV-1 and HSV-2), and human papillomavirus (HPV), which are 
responsible for major sexually transmitted viral infections including AIDS, herpes sim-
plex, and genital warts, respectively. Despite the fact that several prevention strategies 
such as vaccination, abstinence from sex, limiting sex partners, the use of condoms and 
a range of therapeutic drugs have drastically reduced the risk of contracting STIs, these 
three infections continue to spread at an alarming rate. The high incidence and lack of 
effective vaccine, instigated scientists to look for alternate, cheap, and efficient strategies 
for controlling these deadly viruses. Microbicide are relatively new approach that may 
be helpful in preventing STIs transmission when applied inside the genitals before inter-
course. Like other interventions, microbicides are used as prophylactic measures against 
STIs. Therefore, an excellent safety and efficacy profile analysis is mandatory before their 
approval for human use. Although no safe and efficacious microbicide is yet available, 
many candidates including nonoxynol-9, Savvy, cellulose sulfate, Carraguard, VivaGel, 
tenofovir gel, and PRO 2000 have shown promising in vitro activity and many more are 
under development. However, very few of them have moved to large-scale phase III 
trials. This chapter aims to provide a brief overview of various microbicides along with 
their mechanism of actions and recent updates on safety and effectiveness trials.
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1. Introduction
Sexually transmitted diseases (STDs) or venereal diseases (VDs) being responsible for 
millions of deaths worldwide have proven to be a major burden on human health [1]. 
Approximately 19 million new cases of STDs are reported in the United States every year 
[2]. More strikingly, according to Centers for Disease Control and Prevention (CDC) recent 
press release, the largest increase in STD cases was observed from 2014 to 2015. STDs are 
caused by more than 30 different pathogens including bacteria, viruses, parasites, yeast, 
and fungus commonly known as sexually transmitted infections (STIs) (Figure 1). Among 
all known STIs, viruses exhibit more serious risks, probabilities, and outcomes of sexually 
transmitted diseases. Viral STIs include human immunodeficiency virus-1 (HIV), herpes 
simplex viruses 1 and 2 (HSV-1 and HSV-2 ), human papillomavirus (HPV), hepatitis B virus 
(HBV), and molluscum contagiosum virus (MCV) causing acquired immunodeficiency syn-
drome (AIDS), herpes simplex, genital warts, viral hepatitis, and molluscum contagiosum, 
respectively. However, HPV, HIV-1, and HSV-2 targeting the mucosa of the penis, vulva, 
rectum, and urinary tract account for major sexually transmitted viral infections. In order 
to understand the wreckage caused by these infections, it is imperative to understand the 
biology and pathogenesis of the abovementioned sexually transmitted viruses.
1.1. Biology of human papillomavirus
Human papillomaviruses (HPVs) named for warts (papillomas) are the most common sexu-
ally transmitted infectious agents both in men and women across the globe, particularly in 
Figure 1. Sexually transmitted infections (STIs).
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undeveloped countries. It is believed that nearly all men and women acquire HPV infection 
at least once at some stage of their lives [2]. However, sexual transmission being the major 
route of HPV infection, the probability of getting HPV infection in adulthood is high due 
to increased sexual activity. The HPV prevalence falls with the increasing age probably as a 
consequence of decreased sexual activity and establishment of immune response against the 
virus [3].
HPV is a small, nonenveloped, and double-stranded DNA virus having genome size of 8 kbp. 
The circular genome of HPV encodes six early and two late overlapping open reading frames 
(ORFs) and a noncoding long control region (LCR) [4]. Upon infection, the virus first tran-
scribes six early proteins (E1, E2, E4, E5, E6, and E7), which are mainly involved in viral DNA 
replication and HPV-mediated pathogenesis. Late structural proteins L1 and L2, which make 
up the viral capsid, are transcribed during later phases of virus replication [5]. The early 
genes are expressed within the basal surface of the epithelium while late genes in supra-basal 
layer of the epithelium. The LCR located upstream of early and late genes contains various 
promoter and transcriptional regulatory sequences which act as binding sites for several viral 
and host transcription factors [6].
Based on L1 gene nucleotide sequence, the HPVs are classified into genera, species, and types. 
To date, almost 151 types of HPV have been identified and divided into five genera known 
as alpha, beta, gamma, mu, and nu [7]. HPV types are further categorized into cutaneous and 
mucosal types. While cutaneous HPV types target keratinocytes in the hand and feet skin, 
mucosal types infect the inner lining of the respiratory, digestive (mouth, throat, esophagus), 
and anogenital tracts. The cutaneous HPVs mostly belong to beta and gamma genera, whereas 
mucosal types are included in alpha genus [8]. About 30 HPV types have been reported to be 
transmitted through sexual contact, thereby infecting mucosa of the genitalia [9]. The genital 
HPV types are further categorized into high risk (HR) and low risk (LR) based on the severity 
of clinical manifestation. The LR-HPVs such as subtypes 6, 11, 42, 44, 51, 53, and 83 induce 
warts or hyperproliferative benign lesion on genital. On the other hand, HR-HPV subtypes 
including 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,73, and 82 are linked with premalignant 
and malignant cervical, penile, vulvar, vaginal, anal, and head and neck carcinomas [10]. 
Notably, majority of the LR-HPV infections are caused by HPV 6 and 11 subtypes, while 
subtypes 16 and 18 are responsible for most of the HR-HPV infections [11, 12]. In fact, HPV 16 
and 18 are the most lethal subtypes, which together account for 70% cases of cervical cancer, 
the fifth most commonly diagnosed type of cancer and leading cause of cancer deaths [13].
The HPV lesions are believed to commence from the basal keratinocytes, which are exposed 
to HPV infection as a consequence of microabrasions or trauma during sexual intercourse 
[9, 14]. The virus then binds to specific cell surface receptors and is subsequently internalized 
in to the cells where it establishes episomal or integrated persistent infection, a pivotal step in 
cervical cancer causation. Various viral proteins are expressed during the replication cycle of 
HPV that control the transcription as well as replication of virus and induce cell proliferation. 
The E5, E6, and E7 are the essential proteins which help the virus during initiation and pro-
gression of cervical cancer [15]. These oncoproteins interfere with cell cycle and other regu-
latory pathways and induce genome instability mainly by inhibiting key tumor suppressor 
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proteins such as p53 and pRB [16]. The p53 being the guardian of genome is targeted by HPV 
E6 protein for proteasomal degradation, while E7 competes with pRB protein releasing the 
E2F transcription factor, which helps the transcription of genes that drive cell cycle further 
on. Likewise, HPV oncoproteins maneuver host cell in such a way to keep them in a condi-
tion favorable for virus replication. For example, overexpression of E1 and E2 proteins has 
been evidenced to push the cell in S and G2 phases that stably maintain viral episomes [17]. 
HPV has also been described to alter numerous cell regulatory pathways; for instance, E6 and 
E7 are believed to be involved in beta-catenin nuclear accumulation leading to activation of 
Wnt signaling pathway that is one of the major deregulated signal transduction pathways in 
cancer [18]. Another salient example elaborating the role of HPV proteins in carcinogenesis 
was described by Accardi et al. who proved that HPV16 E6 and E7 proteins jointly dissociate 
Na+/H+ exchange regulatory factor-1 (NHERF-1), which is involved in the regulation of vari-
ous cellular processes including signaling and transformation. The degradation of NHERF-1 
leads to activation of the PI3K/AKT signaling pathway, which is known to be a major player 
involved in carcinogenesis [19].
1.2. Biology of herpes simplex virus
Herpes, from the ancient Greek meaning to creep or crawl, is the name ascribed to the infec-
tions caused by a large family of DNA viruses called Herpesviridae. The members of this virus 
family are known to equally infect human and animals. Among the described human herpes 
viruses, closely related herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2) 
that show 70% genomic homology are considered to be most contagious human herpes 
viruses and are transmitted via sexual contact [20]. HSV-1 may be transmitted by oral to oral 
or oral to genital contact, thereby causing oral or genital herpes, while HSV-2 is exclusively 
transmitted by sexual contact and is responsible for genital infections only [21]. Mostly oral 
and genital herpes are symptomless; however, complications can cause painful blisters or 
ulcers at the site of infection. Both of these viruses are widespread in human population. In 
2012, it was estimated that 67% human population under the age of 50 were living with HSV-1 
infection while 11% with HSV-2 [22].
The HSV virion is structurally divided into four parts: an electron dense core containing 
the viral genome, an icosapentahedral capsid, a tegument comprising a protein cluster, and 
a glycoprotein-based envelope [23]. The genome of HSV-1 and HSV-2 is a complex large 
double-stranded DNA molecule which is divided into two unique regions: the long unique 
(UL) and the short unique regions (Us). The UL transcribes 56 viral genes whereas US merely 12 [24]. The translated proteins from these genes are involved in making virus components, con-
trolling virus replication and infectivity. The virus gets entry into the nerve cells in the lower 
layer of the skin as a consequence of interaction between numerous viral glycoproteins and 
host cell receptors mainly heparan sulfate [25]. Upon internalization, the virion is dismantled, 
and capsid is routed to the nuclear pore ejecting its DNA into the nucleus where transcrip-
tion of viral genes takes place with the help of RNA polymerase II [26]. The HSV replication 
involves sequential production of different viral proteins. At first, immediate early proteins 
are synthesized that regulate viral gene expression during replication. The enzymes carrying 
out viral replication are also products of early gene transcription. The late transcribed genes 
predominantly encode proteins required for capsid and envelop formation [24].
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The primary HSV infection occurs in the epithelial cells from where virus ascends to the 
sensory nerve terminal at peripheral site. Then by retrograde axonal transport virus enters 
the trigeminal nerve ganglion and establishes latency resulting in long-time persistence [27]. 
During the latency phase, virus expresses latency-associated transcript (LAT) which regulates 
the host cell genome in order to maintain the virus reservoir in the host without any clini-
cal manifestation [28]. Furthermore, HSV evades host immune response either by mimick-
ing the human interleukin 10 (HIL-10) or by downregulation of the major histocompatibility 
complexes I and II (MHC I and II) in the contaminated cell, thus ensuring virus survival in 
latency [29]. The HSV encodes a HIL-10 homologous protein that blocks the production of 
pro-inflammatory cytokines such as IFN-γ, IL-1α, GM-CSF, IL-6, and TNF-α, thereby reduc-
ing the natural killer cells and cell-mediated response against virus [30]. Likewise, for the 
downregulation of MHCI-II, HSV encodes ICP47 protein that blocks the presentation of 
MHC-class-1 proteins on the cell surface by retaining the newly synthesized MHC molecules 
in the endoplasmic reticulum [31]. The lack of MHC expression on the surface of infected cells 
results in the absence of T-cell activation ultimately helping virus to hide from the immune 
system. In some infected persons, viral reactivation occurs sporadically due to some trigger-
ing factors such as physical or emotional stress, fever, ultraviolet light, tissue damage, and 
other immune-compromising events [32]. Upon activation, virus travels from the dorsal root 
ganglion in conjunction with sensory nerve cells to the epidermal-dermal junction. During 
virus activation phase, a transition in the gene expression takes place, and virus expresses 
multiple lytic genes which direct the elevated viral replication and host cell death on the other 
hand [28]. The active virus is ultimately transported to the skin again where virus sheds and 
initiates new cutaneous or mucosal sores.
1.3. Biology of human immunodeficiency virus
Human immunodeficiency viruses (HIV) are members of Retroviridae family, which cause 
disease in both genders of almost all ages. Though two closely related HIV types (HIV-1 and 
HIV-2) have been described, however, HIV-1 is more virulent and is responsible for majority 
of HIV-related infections [33]. This virus is known to infect cells of the immune system includ-
ing macrophages and dendritic and CD4+T cells, thereby destroying them and impairing host 
immune function [34]. If left untreated, HIV infection may lead to a devastating disease called 
acquired immunodeficiency syndrome (AIDS). It is estimated that during 2015 alone, 36.7 
million people got infected with HIV, while 1.1 million died of HIV-related causes worldwide.
The HIV is a tiny enveloped virus consisting of two copies of positive sense RNA molecules, 
which are accompanied by several nucleocapsid proteins and enzymes, for instance, prote-
ases and integrases [35]. The genome of HIV is complex and for the most part marked as 
5′LTR-gag-pol-env-LTR′3 [36]. However, six other genes—tat, rev, nef, vif, vpr, and vpu are also 
encoded by virus genome. The gag (group antigens) and env genes encode major nucleocapsid 
and structural proteins, while pol transcribes enzymes such as reverse transcriptase required 
for virus replication [35]. In fact, the gag, pol, and env proteins act as precursor and cleaved by 
proteases to give rise several other proteins. The remaining six genes are considered as acces-
sory genes which are required for efficient virus replication and for regulation of viral gene 
expression [37]. Among these six accessory proteins, nef and vif are of extreme importance 
as they help virus in immune evasion and deal with antiviral activity of host APOBEC3G 
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protein. The nef reduced the antigen presentation on the HIV-infected cells, thereby hiding 
from the immune system, while vif neutralized the infectivity of APOBEC3G protein, which 
degrades the viral RNA in the infected cell [38].
The HIV targets CD4+ T cells, macrophages, and dendritic and microglial cells for its mul-
tiplication. The life cycle of the virus begins with the virus attachment to CCR5 and CXCR4 
receptors through its trimeric glycoprotein complex made up of gp120, gp160, and gp41. The 
surface proteins of HIV fuse with host cell membrane releasing viral genome inside the cells. 
The virus ssRNA is converted into complementary DNA (cDNA) by utilizing virus enzymes 
that are the part of mature HIV virion. The complementary part of the cDNA is synthesized 
and then transported to the nucleus where it integrates into host genome as provirus again 
with the help of virus-encoded integrase enzyme [39]. The integrated genome is transcribed 
into mRNA which is utilized simultaneously to produce viral proteins as well as the viral 
genome. The viral-encoded proteins tet and rev regulate the expression of HIV genes. For the 
synthesis of HIV virion, structural protein gp 160 is transported to the cell membrane where 
all virus components are assembled and finally bud off from the cell [40].
The destruction of CD4+ T cell is the mainstay mechanism of HIV-mediated pathogenesis. 
The HIV reduces the number of CD4+ T cells by several mechanisms. Programmed cell death 
or apoptosis is among the most prominent mechanisms underlying HIV-mediated destruc-
tion of CD4+ T cells [41]. The increased apoptosis of CD4+ T cells in HIV infection could be 
due to direct viral cytotoxicity or due to signaling events triggered by viral proteins. The 
apoptosis in HIV-infected patients is not limited to infected T cells only, but uninfected cells 
are also destroyed by the so-called bystander mechanism. While several viral proteins are 
believed to play a role in apoptosis of bystander CD4+ T cells, interactions between viral Env 
glycoprotein expressed on surface of infected T cells and specific receptors and coreceptors 
on the surface of neighboring uninfected T cells have been proposed as the major mechanism 
responsible [42]. The bystander apoptosis reduces the number of T cells to an alarming level 
making the person more likely to get other opportunistic infections including viruses and 
bacteria that put the life in serious danger [43].
2. Conventional methods for the prevention of STIs
Ever since their discovery, successful prevention and treatment of STIs, including HIV-1, 
HSV-2, and HPV, have been a high-priority research area. To date, several recommendations 
with varying effectiveness have been put forward by researchers and healthcare providers in 
order to limit STIs. The focal point of these described strategies is the prevention, i.e., blocking 
the acquisition of STIs. The STI prevention approaches are mainly based on reducing the risk 
factors, deployment of physical barriers, prophylactic immunization against sexually trans-
mitted agents, efficient and timely diagnosis of STIs, and treatment of active infection [44, 45]. 
There has been remarkable progress in the diagnosis and treatment of STIs; however, the 
discussion on them would be beyond the scope of this chapter. Nevertheless, other preventive 
measures against STIs particularly HIV-1, HSV-2, and HPV will be discussed thoroughly in 
the coming sections of this chapter.
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2.1. Curtailing risk factors for STIs
The act of sexual intercourse in humans is known to create small unnoticeable microabrasions 
which in turn pave the way for entry of numerous STIs. The epidemiological synergy has 
also hinted that the presence of some STIs favors the acquisition of other STIs. For instance, 
the existence of chlamydia, herpes, gonorrhea, and syphilis in an infected person makes him/
her more likely to acquire HIV infection [46]. It is also worth mentioning that multiple STI 
coinfections prove to be more harmful than the single STI [47]. Therefore, the paramount 
approach in treating STDs would be to combat the transmission of STIs altogether. This could 
only be achieved by reducing risk factors, such as unprotected sex, early age sex, and multiple 
sex partners that increase the chances of catching various STIs [48].
The most reliable way of controlling STDs is the complete abstinence from any type of sex 
particularly during teen ages and comprehensive sex education [49]. Nevertheless, this does 
not seem to be a practical approach. However, limited number of sex partners and long-term 
sexual relationship with a single uninfected individual are believed to be most pragmatic 
ways in this regard [50]. Talking with partners about sexual health prior to sexual activities 
also mitigate the risk of getting STIs. Some important considerations before, during, or after 
sexual intercourse such as washing ahead of performing sex, avoiding sex when drunk, and 
circumvent unharmful sex positions have significantly reduced the STI burden [51]. Recently, 
male circumcision has been reported as a vital mean of reducing STI risk. Three separate clini-
cal trials have demonstrated that circumcision can reduce the HIV acquisition by 60% [52, 53]. 
Moreover, male circumcision was also found to be effective against other STIs including HPV 
and HSV-2 [54].
2.2. Putting the physical barriers to STIs
The use of physical barriers, including male and female condoms, is not only among the most 
commonly used birth control methods but also serves to curtail the spread of STIs effectively. 
Male condoms are classified into natural or synthetic categories based on the material they 
are made of. Natural membrane condoms usually derived from lamb cecum are primarily 
meant for pregnancy prevention rather stopping STIs. In fact, the pores in the natural con-
doms are large enough to let the passage of small STI-causing organisms, particularly viruses 
[55]. On the other hand, the efficacy of synthetic condoms in the prevention of STIs has been 
proved by various epidemiological and laboratory studies [55]. Synthetic condoms are either 
made of latex or other nonlatex material such as polyurethane or polyisoprene. Latex con-
doms are flexible, broadly available, and least expensive among all types of condoms. They 
are exceedingly effective in preventing the sexual transmission of plethora of STIs, including 
HPV, HIV-1, and HSV-2 [56–58]. The failure of latex condoms to safeguard STIs or unin-
tended pregnancy is usually due to inconsistent or incorrect use [59]. The nonlatex condoms 
are particularly suitable for those allergic to latex. Polyurethane condoms are relatively thin 
and odorless. They provide comparable protection as of latex condoms against various STIs 
[60]. However, polyurethane condoms are at higher risk of breakage during intercourse. Both 
latex and nonlatex condoms’ efficiency of protecting STIs can be enhanced by using some 
germicidal spray on them [61].
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Female condoms are usually made up of thin plastic polyurethane material and have rings on 
the both ends. The ring inside the vagina covers up the cervix with a plastic sheet while outer 
ring is open and resides outside the vagina covering the vulva. Like male condoms, these are 
designed to avoid pregnancy as well as to prevent the infection spread during sexual process 
[62]. Female condoms are usually recommended to sex partner when male condoms can-
not be used appropriately. Contradictory reports have been presented regarding efficiency of 
female condoms. One systemic review based on different randomized control trials revealed 
that female condoms are good in avoiding pregnancy but not in protection from STIs [63]. 
On the contrary, another randomized control trial concluded that female condoms’ efficacy 
is comparable with male condom [64]. As a matter of fact, the female condom efficiency like 
male condom varies according to their use. In the nutshell, it has been estimated that female 
condoms are more efficient if used consistently with accuracy [65].
Another way of protecting pregnancy and STD in females is the use of cervical diaphragms. 
Diaphragm is a dome-shaped bowl made of thin and flexible rubber that sits over the cervix. 
In order to use it as a contraceptive, spermicide is placed into the bowl and edges of the 
diaphragm before inserting into the vagina [66]. After sex, the diaphragms are left inside 
the vagina at least for 6–24 h. There is ample epidemiological and biological data suggesting 
that diaphragm use can reduce the risk of acquiring some of the STDs including gonorrhea, 
chlamydia, and trichomoniasis [57]. However, diaphragm has been proved to be ineffective in 
reducing the risk of acquiring HIV infection. Moreover, spermicide use along with diaphragm 
increases the risk of bacterial urinary tract infections [67]. It is therefore recommended that 
targeted clinical trials must be conducted before approval of diaphragms as a method for STI 
prevention.
2.3. Immunization against HPV, HIV-1, and HSV-2
Vaccines prime individuals’ immune response to build up adaptive immunity, thereby pro-
tecting them from subsequent infection. Preexposure vaccination probably is the most effec-
tive means of preventing transmissible infection including STIs [51]. Unfortunately, except for 
HPV, no vaccine is approved for other sexually transmitted viral infection. However, vaccines 
against HIV-1 and HSV-2 are under developmental phase. Table 1 enlists and describes char-
acteristics of all proposed vaccines for HPV, HIV-1, and HSV-2.
HPV vaccine being a major public health breakthrough is administered in both males and 
females before reaching the age where HPV risk is maximum. Up till now, three HPV vac-
cines under the trade name of Cervarix, Gardasil, and Gardasil 9 have been approved by 
FDA [68]. The Cervarix is bivalent vaccine designed against HPV types 16 and 18 that are 
responsible for 70% cervical cancer. In addition to HPV 16 and 18, Gardasil provides protec-
tion against HPV 6 and 11, which cause 90% of genital warts [69]. The Gardasil got approved 
from FDA in 2006 while Cervarix in 2009. Recently in 2014, another vaccine Gardasil 9 was 
approved and is meant to protect against 9 HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58 
(FDA press release). All these vaccines are administered in a series of three doses at the ages 
of 16–26. However, they can be administered up to the age of 45. The effectiveness of all these 
vaccines has been assessed clinically in many randomized controlled trials, and all these trials 
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endorsed the safety of these vaccines [70, 71]. Likewise, HPV vaccine is safe and is associated 
with no or mild side effects such as fever, nausea, and headache. The available HPV vaccines 
have noticeably reduced the incidence of genital warts, cervical intraepithelial neoplasia, as 
well as cervical cancer worldwide [72].
Several preventive and therapeutic antiherpes vaccines are under different developmental 
stages, but no vaccine has been approved so far. Most of these vaccines target HSV-2 rather 
than HSV-1. Nonetheless HSV-2 vaccine would also be effective against HSV-1 because of 
homology between two viruses. Nowadays, several approaches have been used by academic 
institutes, government agencies, and pharmaceutical companies who are engaged in devel-
oping and testing HSV vaccines. Most of the endeavors are based on the concept of using 
virus glycoproteins to design subunit vaccine. The largest clinical trials were conducted on 
“Herpevac” vaccine which employs virus glycoprotein D-2 (gD2) as immunogen. These trials 
showed that vaccine provided significant protection against HSV-1 but not HSV-2 [73]. A rep-
lication-defective HSV-2 vaccine (HSV529) has also entered phase I trials [74]. One live attenu-
ated vaccine has produced marvelous results in the mouse model. However serious concerns 
have been noticed regarding the safety of this vaccine. One of the important points for the 
Virus Vaccine name/
pharmaceutical 
company
Vaccine type For which type Clinical status
HPV Gardasil/Merck & Co. Recombinant HPV 16, 18, 6, and 11 FDA approved (2006)
Cervarix/
GlaxoSmithKline
Recombinant HPV 16, 18 FDA approved (2009)
Gardasil 9/Merck 
& Co.
Recombinant HPV 6, 11, 16, 18, 31, 
33,45, 52, and 58
FDA approved (2014)
GEN-003/Genocea HSV subunit vaccine HSV-1 and HSV-2 Phase II
HerpV/Agenus Peptide vaccine HSV-1 and HSV-2 Phase II completed
HSV Vical HSV-2 
(therapeutic vaccine)/
Vical
DNA vaccine HSV-2 Phase II
Shingrix/
GlaxoSmithKline
Subunit vaccine HSV-2 Phase III
HSV-529/Sanofi Live attenuated 
vaccine
HSV-2 Phase I
gD2t/
GlaxoSmithKline
Synthetic vaccine HSV-2 Phase II completed
AGS-004/Argos Therapeutic vaccine HIV-1 Phase IIb
HIV GTU multi-HIV+ 
Lipo5
DNA+ lipopeptide 
vaccine
HIV-1 Phase II
VAC-3S InnaVirVax Peptide based HIV-1 Phase II
Table 1. The list and characteristics of all available/proposed vaccines against HPV, HIV-1, and HSV-2.
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failure of HSV-2 vaccine is the nonavailability of suitable animal model for HSV. Due to spon-
taneous reactivation in the genital tract, guinea pigs are considered a better model than mice 
[75]. For the last decade, almost three anti HSV-2 vaccines, namely, GEN-003, HerpV, and gD/
UL46, have entered phase I/phase II clinical trials. These vaccines were designed to stimulate 
T-cell immunity.
It has now been more than a quarter century that researchers are engaged in finding an effec-
tive measure that can provide a significant degree of protection against HIV infection. Some 
promising advances regarding HIV vaccine development have been witnessed during last 
two decades, but an effective and safe HIV vaccine is still needed. In fact, HIV being an RNA 
virus exhibit high mutation rate and hence increased genetic variability. This particular aspect 
of HIV biology is the main reason hindering HIV vaccine development efforts [76]. A range of 
approaches are being tested for developing an effective HIV vaccine such as protein subunit 
vaccines, viral vectors encoding for HIV proteins, DNA vaccines, as well as prime-boost strat-
egy that uses a canarypox viral vector encoding HIV Env, Gag, and Pol proteins to prime the 
immune system followed by a mixture of same protein subunits as booster dose [77]. All these 
approaches employed one of the three scientific concepts that include induction of neutral-
izing antibodies, cell-mediated immunity, and exploration of combination approaches [76]. 
The vaccines being developed for HIV prevention have been subjected to clinical trials for 
safety and efficacy analysis. The VAX003 and VAX004 were the first efficacy trials of bivalent 
HIV vaccine, conducted by in men who have sex with men (MSM) and injection drug users 
[78]. These phase III trials show that vaccine was not effective in preventing HIV disease 
progression [79]. Similarly, two trials—HVTN 502 and HVTN 503 also called “Step Study” of 
Adenovirus vector-based HIV vaccine—failed to prove the efficacy of vaccine. HVTN 505 vac-
cination trials were also stopped in 2013 because initial results revealed that the vaccine was 
ineffective in preventing HIV infections [80]. However, the encouraging results were obtained 
in RV144 trials of HIV vaccine where it has noticed that vaccine reduced the infection in 31% 
cases [81]. This was the only trial that showed somewhat positive results.
3. Microbicides for the prevention of STIs
As mentioned in preceding discussion, a range of preventive strategies with varying degrees 
of efficacy and efficiency have been employed to curtail the transmission of HPV, HIV-1, and 
HSV-2 infections. However, these three deadly viruses continue to spread at alarming rates. 
Increasing incidence and failure in the development of effective HIV-1 and HSV-2 vaccines 
have instigated scientists to explore alternate research avenues. As STI spread is directly cor-
related with socioeconomic status of subjects, economically disadvantaged population being 
at high risk, there is also a dire need for cheaper options.
Microbicides are antimicrobial compounds claimed to be helpful in controlling the transmis-
sion of STIs upon self-administration inside the vagina and rectum. Some of the microbicides 
have been witnessed to provide considerable protection against STIs including HIV-1, HPV, 
and HSV-2 [82]. However, it is not clear whether microbicides render anticontraceptive effect 
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too. Ideal microbicides are colorless, odorless, and tasteless compounds available in differ-
ent biological formulations such as gels, creams, rings, suppositories, pessaries, films, and 
invisible condoms. Other criteria for microbicides to be ideal are safety and effectiveness in 
preventing broad range of STIs. Moreover, its repeated use should cause minimal or no symp-
toms in the vagina or rectum. The microbicides as STI-controlling measure are advantageous 
in many ways. In comparison to other interventions, microbicides are cheap, offered over the 
counter, and available in many formulations [83]. They can be easily applied by women them-
selves and do not create a physical barrier to intimate contact. Similarly sex worker can apply 
them without prior information to their clients. Moreover they are safe and nonirritating.
Currently, more than 50 potential microbicide agents have been identified. However, very 
few of them proved to be effective and have gone under advance phase III clinical trials [84]. 
The coming section of this chapter will provide a comprehensive review of various microbi-
cides, along with their mechanism of action and current status of clinical trials, in order to 
highlight their strengths and shortcomings.
3.1. Stages in microbicide development
Drug development is a long-term work, which can even be of a decade or more sometimes. 
The microbicide development would have to follow the same protocols of drug development 
as any other drugs do [85]. The development of drug starts with the insight of the researchers 
to a new potential compound or chemical that can hinder or stop the cascade of destruction by 
the infection or to eliminate the pathogen as well. So once the potential candidate from many 
compounds is isolated for research and development of drug, then every aspect of it is practi-
cally assessed like its absorbance, distribution, destabilization, mechanism of action, dosage 
and side effects, etc. Then comes the preclinical testing of the drug, which can be in vitro or 
in vivo. Once the pre-clinical testing is complete, the clinical trials of the drug will show how 
it works in the real system. There are four phases of the clinical trials from 1 to 4 depending 
upon the no. of volunteers assigned to it, the duration of the phase, and the purpose of testing. 
Phase I of clinical trials is to assess safety and dosage, and almost 70% of the drugs pass this 
phase. Phase II clinical trial is to judge efficacy and side effects of the drug and could take up 
to 2 years, and 33% of the drugs pass it. In phase III, efficacy and adverse reactions are moni-
tored, and about 25–30% move to the next level [86]. In phase IV, several thousands of vol-
unteers are involved, and safety and efficacy of the drug are observed. If the drug shows the 
satisfactory results in all phases of trials, then it got reviewed by the drug regulatory authority 
that then monitors the marketing and follows active surveillance. The developmental phases 
of microbicides are summarized in Figure 2.
3.2. Microbicide mechanism of STI prevention
Microbicides exert their antimicrobial function by a range of mechanisms which can be 
divided broadly into four categories: vaginal defense enhancers, inactivation of virus in the 
vagina, virus attachment and fusion inhibiters, and virus replication inhibitors. Figure 3 
enlists some categories of microbicides and their mechanism of action altogether.
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Figure 3. Categories of microbicides along with their mechanism of action.
3.2.1. Vaginal defense enhancers
Naturally, the acidic pH of the vagina provides an established defense against invading 
infections. Some organisms such as lactobacilli being natural inhabitant of the vagina play a 
pivotal role in maintaining the low vaginal pH [87]. This organism also releases some antimi-
crobial compounds, for instance, lactic acid, hydrogen peroxide, bacteriocins, and biosurfac-
tants, which keep the vagina protected from pathogens. However, semen and some bacterial 
Figure 2. Phases of microbicide development.
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 infections increase the pH, thereby making the vagina more likely to catch infections includ-
ing STIs [88]. Some acid-buffering microbicides can reduce the pH of the vagina to make it 
protected again from STIs. The pH-reducing microbicides include AcidForm and BufferGel. 
The microorganism such as Lactobacillus crispatus replacing missing Lactobacillus could also be 
important in enhancing vaginal defense [89].
3.2.1.1. BufferGel
BufferGel is a polymer of buffering Carbopol which is osmotically balanced with some 
physiological salts. They are not irritating for the genital surfaces and therefore can be used 
along with condoms or diaphragms. It helps to maintain the acidic pH of the vagina even in 
the presence of semen, thereby reducing the germ flow inside the female genital tract. The 
BufferGel has been reported to reduce the bacterial population in the vagina other than 
Lactobacillus, thus maintaining the natural milieu of the vagina [90]. The phase I clinical trials 
for BufferGel showed satisfactory results, and the agent was tolerated well by subjects [91, 92]. 
These trials also endorsed the potential of BufferGel to avoid pregnancy and to check the trans-
mission of HIV-1, HPV, HSV-2, and chlamydia infections. However, phase III trial results failed to 
exhibit required performance level; therefore further production of BufferGel was abandoned [93].
3.2.1.2. AcidForm
AcidForm is another buffering gel used as spermicidal and microbicide. The mode of action 
of this gel is to maintain the vaginal acidity for a long period of time, hence protecting the 
vaginal and cervical epithelium from pathogens. This buffering gel is reported to be effective 
against HSV, chlamydia, gonorrhea, HPV, and HIV-infected leukocytes. Besides the protec-
tion from STIs, it can also act as contraceptive [94]. AcidForm trials for assessment of safety 
and bactericidal activity showed that it may augment mucosal defense. However, AcidForm 
was associated with more irritation than placebo and lower levels of antimicrobial (lactofer-
rin) and anti-inflammatory (IL-1ra) [95]. Currently, AcidForm has cleared phase I safety trials, 
while phase III trials are in progress for this buffering microbicide [96, 97].
3.2.2. Inactivation of virus in the vagina
First-generation detergents and surfactants, for example, Nonoxynol-9, sodium dodecyl sul-
fate (SDS), and Savvy (1% C31G), kill viral infection by disrupting their outmost coverings, 
i.e., envelope or capsid, thereby causing their destruction [98]. These types of microbicides are 
equally dangerous for the normal cells of the genital mucosa. Initial clinical trials showed their 
ineffectiveness in controlling the transmission of STIs including HIV-1. On these grounds, 
further trials were abandoned. Nonetheless, broad-spectrum viral inactivating topical micro-
bicides are a promising agent for fight against STIs; therefore, efforts to develop novel drugs 
as well as combination regimes are ongoing.
3.2.2.1. Nonoxynol-9
Nonoxynol-9 (Nonylphenoxypolyethoxyethanol or N-9) was one of the earliest known sper-
micidal compounds that have been clinically evaluated as topical microbicides against HIV 
transmission [99]. Nonoxynol-9 is the active ingredient in most of the spermicidal and is 
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 available over the counter in the form of creams, jellies, foams, gel, film, and suppositories. 
In various clinical trials, Nonoxynol-9 was proved to be a good spermicidal but not effec-
tive against STIs. Two phase III clinical trials in Africa demonstrated that Nonoxynol-9 does 
confer any protection against HIV in comparison to the placebo. In addition, its use increases 
the risk of genital diseases and even contracting HIV [100]. It was lately revealed that N-9 
induces superficial de-epithelialization and high rate of petechial hemorrhages, thereby mak-
ing the genital mucosa prone to other infections [101]. On these grounds, the World Health 
Organization (WHO) recently asked to include the sentence “this product does not block 
STIs” in the labeling of that compound [84].
3.2.2.2. Savvy (1% C31G)
Savvy or C31G (Cellegy Pharmaceuticals, Quakertown, PA, USA) is another spermicidal 
and antimicrobial surfactant containing acetyl betaine and myristamine oxide. The mode of 
action of Savvy is not much different from the N-9 but with less side effects. Moreover it has 
the ability to be quickly dissolved and spread on the genital mucosa [90]. At very low con-
centration like 0.001%, it has shown very minimum toxicity in preclinical trials and even no 
toxicity at 0.003% to mammalian cells as measured by MTT assay [99]. Several in vitro studies 
have suggested that C31G (Savvy) has the ability to disrupt the outer membrane of HIV [104]. 
Although, in phase I trials, Savvy proved to be safe in use, its production was stopped several 
years ago due to ineffective results in phase III clinical trials in Ghana and Nigeria [84].
3.2.2.3. Sodium lauryl sulfate
Because of the limitations of N-9, efforts have been directed toward the development of sec-
ond-generation microbicidal agents with broader activity and lower toxicity. Sodium lauryl 
sulfate (SLS) is an anionic surfactant and has recently been tested as novel microbicidal 
agent that demonstrated significant lethal activity against a broad spectrum of STD patho-
gens, including HIV-1 [102]. This agent behaves as a liquid at room temperature and con-
verts into gel form at body temperature to protect the STI transmission [103, 104]. Therefore 
it can be used as invisible condoms. Two phase II trials in Cameron revealed that SLS is safe 
to use intravaginally for long period of time and can be moved on to phase III trials [105].
3.2.3. Virus attachment and fusion-blocking microbicides
Second-generation microbicides are designed to block the entry of STI-causing pathogens into 
the susceptible host cells. These agents usually interfere with viral entry process by altering 
or blocking cellular receptors that are the first attachment sites for the pathogens. Receptor-
blocking microbicides act both by nonspecific and specific mechanisms. The former mecha-
nism blocks the attachment of multiple organisms, while latter mechanism hinders the entry 
of specific organism, for example, targeting CD4 receptors for the blockage of HIV entry [106].
3.2.3.1. Carrageenan
The carrageenan is an unbranched sulfated polysaccharide belonging to polyanoin class and 
extracted from red algae. It is chemically similar to heparan sulfate, which is used as receptor 
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by many pathogens to initiate the entry. These entry inhibitors work through electrostatic 
interaction with the viral surface proteins. The negatively charged polyanoin molecules may 
neutralize the positively charged surface of virus, for instance, HIV, thereby blocking attach-
ment and entry into the healthy target cells [107].
It is in rife commercial use as a thickener in a number of products including cosmetics, food 
products, sexual lubricants, and infant feeding formulas. It has also been reported as an 
extremely potent inhibitor for a broad range of sexually transmitted infections [84]. This tropi-
cal microbicide has been proven to block HPV infectivity in vitro, even when diluted a mil-
lion-fold. Carrageenan prevents the binding of HPV virions to the host cells and is observed 
to be more potent than heparin, a form of cell-free heparan sulfate that has been regarded as 
a highly effective HPV inhibitor. Carrageenan can also block HPV infection through a second, 
post-attachment heparan sulfate-independent effect. Besides HPVs carrageenan can inhibit 
HSV-2 and some strains of HIV-1 in vitro [108].
Two preparations of carrageenan, polynaphthalene sulfonate (PRO 2000) and Carraguard, 
have been introduced. Both the products strongly bind to STI pathogens including HIV-1, 
HPV, and HSV-2. Both of the carrageenan preparations have been proven to be safe in phase 
I clinical trials albeit in low doses. However, in phase III trials, these products proved to be 
ineffective; therefore, further trials were abandoned [109].
3.2.3.2. Cellulose sulfate
Polyanion cellulose sulfate is another long-chain sulfated polysaccharide that is being developed 
as a contraceptive and microbicidal agent. It has manifested in vitro activity against a broad spec-
trum of sexually transmitted pathogens. Moreover, inhibitory effect was marked up to 8 h after 
initiation of infection [84]. Cellulose sulfate has antimicrobial activity in vitro against various 
sexually transmitted pathogens including Neisseria gonorrhoeae, Chlamydia trachomatis, and HIV-
1. It has been shown to bind with HIV-1 gp120 and block its interaction with D4+ receptors [110]. 
Phase I safety studies revealed that cellulose sulfate is safe and well tolerated [111]. However, 
in phase III trials, it failed to protect against HIV and tends to increase the risk of infection [111].
3.2.3.3. VivaGel
VivaGel belongs to dendrimers that are new members of polyanoin family and are highly 
branched nanoscale macromolecules having various surface features. These macromolecules 
have recently been described as microbicides with considerable safety and effectiveness 
[112]. Dendrimers utilize polyvalent interactions for binding and initiating biologic activ-
ity. VivaGelTM (SPL7013) is a commercial polyanion dendrimer developed by Starpharma 
(Melbourne, Australia). It is a water-based vaginal product in the form of mucoadhesive gel 
containing 3% w/w active ingredient and is administered in the vagina alone or mixed in 
Carbopol buffered gel that is used to maintain the physiological pH of the vagina [113]. It was 
developed for specific binding to surface proteins of virus, thereby blocking their attachment 
with the receptors of host cells. For instance, in the case of HIV, it binds with gp120 protein 
which virus use to attach CD4+ T cells. Several trials have been conducted to evaluate the 
safety and efficacy of this product. These studies unanimously describe that SPL7013 is non-
toxic and safe to use even at very high concentrations of (1000 μg/ml) [112, 114]. Likewise, in 
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vitro trials showed effectiveness in inhibition of HIV-1 and HSV-2 infections in human cell 
lines as well as macaque PBMCs. Recognizing its potential, the FDA included VivaGel™ in 
Fast Track status since January 2006 for the prevention of HIV indication. Recently in 2016, 
Starpharma announced the completion of enrollment for phase III trial of VivaGel effective-
ness in preventing the bacterial vaginosis and several STIs including HIV and HSV-2. Trial 
results are now expected in the first quarter of 2017.
3.2.4. Virus replication inhibitors
Unlike previously described microbicides, third-generation microbicides work by interfering 
with a specific step of virus replication cycle when administered locally on the mucosa. The 
most widely studied examples of virus replication blocker are antiretroviral (ARV) microbi-
cides, which can be divided into nucleoside reverse transcriptase inhibitors (NRTI) and non-
nucleoside reverse transcriptase inhibitors (NNRTI). Both of these ARV microbicides block 
the activity of HIV reverse transcriptase enzyme that is required for the conversion of RNA 
into DNA, an essential step required for integration of HIV into the host genome [115]. This 
blockage ultimately reduces the number of HIV virions in the infected cell. These next-gen-
eration microbicides are formulated in the form of long-acting vaginal ring, film, or gels. In 
addition to other benefits, the reverse transcriptase inhibitor class of microbicides is also cost-
effective. Some of the ARV examples being tested include tenofovir, dapivirine, and UC-781.
3.2.4.1. Tenofovir
Tenofovir is a highly acclaimed antiretroviral drug which obstructs the virus growth inside the 
host cells. It is usually taken in the form of pills, and it has become a necessary component of 
the three-drug cocktail for antiretroviral therapy approved by the FDA [116]. However, it has 
also been prepared in the form of gels to be used as topical microbicides. The gel preparation 
of tenofovir is currently under assessment as a tropical microbicide for the prevention of HIV 
infection in high-risk populations, and several safeties and efficacy-related trials are underway.
A study known as “CAPRISA 004” completed by scientists at the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA) in 2010 revealed that 1% tenofovir gel 
application before and after sex was 39% efficient in reducing a woman’s risk of getting 
infected with HIV and 51% effective in preventing genital herpes infections [117]. Moreover 
in this study, the protective effect against HIV increased with gel adhesiveness and increased 
use of tenofovir. For example, 54% reduction in HIV infections was observed in women who 
used gel in more than 80% of their sex acts, whereas those who used the gel in less than half 
of their sex acts had a 28% reduction in HIV infections. The efficacy of tenofovir gel for the 
prevention of HIV was also evaluated in another study known as VOICE. Unlike CAPRISA, 
this study reported that tenofovir preparation does stop the transmission of HIV-1 [118]. 
However, poor adherence was employed by the participants of this trial.
Another trial on tenofovir gel known as “The FACTS 001” was conducted to evaluate the 
reproducibility of the CAPRISA 004 trial results. The results of this trial were announced on 
February 24, 2015. Disappointingly, the study did not confirm the pericoital tenofovir gel 
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effectiveness. In this trial, the gel only showed a protective effect when used consistently and 
covered most of the sex acts, but most women in this trial were unable to use it in this manner. 
However, the gel appeared to be acceptable and easy to apply for most of the women [119]. 
Very recently, the use of tenofovir on the genital mucosa has been linked with some toxic 
effects such as suppression of anti-inflammatory mediators, increased T-lymphocyte infiltra-
tion of the mucosa, and induced mitochondrial dysfunction, which were noticed [105]. These 
unexpected results led to tenofovir gels being dropped from a large ongoing clinical trial.
3.2.4.2. UC-781
UC-781 is a hydrophobic thiocarboxanilide nonnucleoside reverse transcriptase inhibitor 
(NNRTI) developed as antiretroviral drug having high affinity for HIV reverse transcrip-
tase. This agent eagerly crosses membrane barriers and inactivates reverse transcriptase even 
before entry into the cell, thereby acting as potent antiretroviral agent. However the produc-
tion of it as antiretroviral drug was abandoned due to poor bioavailability. Later on, this agent 
was developed in the form of tropical formulation. Phase I safety trials confirmed its safety 
for vaginal application at lower concentrations [120]. Recently UC-781 in the form of vaginal 
ring has been reported to provide strong protection against HIV transmission. Moreover no 
toxicity was observed in this study [121]. Further large-scale clinical trials are required before 
the UC-781 microbicide gel formulation reported to be successful in the prevention of HIV-1 
sexual transmission.
3.2.4.3. Dapivirine
Dapivirine being nonnucleoside reverse transcriptase inhibitor has been reported to act as 
microbicide against various STIs, particularly HIV-1. It is reported to have dual mode of action 
against HIV-1; it inhibits both viral entry and reverse transcription stopping the conversion 
of viral RNA to proviral DNA. Because of dapivirine’s tight binding and lipophilic character-
istics, it may be active against both cell-free and cell-associated HIV [122]. Dapivirine is the 
only microbicide used in human in the form of vaginal rings and believed to be nontoxic [123]. 
The phase III clinical trials (the ASPIRE study) showed a 27% reduction in HIV-1 acquisition 
upon using dapivirine vaginal rings [124]. The protection effect was more pronounced in the 
women aged 21 or more; however, no significant protection was observed for women under 
age 21 [10]. Another phase III trial for efficacy evaluation of dapivirine is in progress.
4. Conclusion and future prospects
Microbicides offer an accessible, easy-to-use, and low-cost option for the control of sexually 
transmitted infections and hence have been an area of high interest for scientists and research-
ers around the world. However, progress in this area has been dismal, and very few micro-
bicide drugs have so far been able to enter the market. With ever-growing epidemic of STIs, 
particularly in less developed areas of the world, there is an immediate need to gear up con-
certed efforts for the development and discovery of novel microbicide compounds. Moreover, 
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it is imperative that efforts should be made to develop novel delivery methods to improve the 
efficacy of existing microbicides. Results from recent trials can guide for more development of 
more rationally, accurately, behaviorally, and socially accepted and single solution maximum 
potential STIs.
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